Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in Non-Metastatic Hormone-Refractory Prostate Cancer
NCT00036556Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jun 2001
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Atrasentan Arm with Placebo Arm (2 arms). Primary endpoint: Time to Disease Progression. Started Jun 2001; status: completed.
02
Drugs
atrasentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00036556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036556.